Warfarin underused in elderly women with AF
1
Inpharma 1294 - 30 Jun 2001 Warfarin underused in elderly women with AF Elderly women with atrial fibrillation (AF) are less likely to receive warfarin than elderly men, report researchers from Canada. Their 3-year study included data for 773 patients with newly diagnosed AF enrolled in the Canadian Registry of AF (CARAF). * The overall use of antithrombotic agents, or of other cardiac medications, did not differ significantly by gender. However, among patients aged ≥ 75 years with ≥ 1 stroke risk factor, women were significantly less likely to receive warfarin than men (24.5 vs 44.9%). On the other hand, women aged ≥ 75 years were twice as likely to receive aspirin, compared with men of that age group. The analysis also showed that women receiving warfarin were 3.35 times more likely to experience a major bleed than men receiving warfarin. * This study was supported by Procter and Gamble Pharmaceutical Canada, Inc. CARAF received support from Knoll Pharmaceuticals and DuPont Pharma. Humphries KH, et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 103: 2365-2370, 15 May 2001 800867957 1 Inpharma 30 Jun 2001 No. 1294 1173-8324/10/1294-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Warfarin underused in elderly women with AF
Inpharma 1294 - 30 Jun 2001
Warfarin underused in elderlywomen with AF
Elderly women with atrial fibrillation (AF) are lesslikely to receive warfarin than elderly men, reportresearchers from Canada.
Their 3-year study included data for 773 patients withnewly diagnosed AF enrolled in the Canadian Registry ofAF (CARAF).* The overall use of antithrombotic agents,or of other cardiac medications, did not differsignificantly by gender. However, among patients aged≥ 75 years with ≥ 1 stroke risk factor, women weresignificantly less likely to receive warfarin than men(24.5 vs 44.9%). On the other hand, women aged ≥ 75years were twice as likely to receive aspirin, comparedwith men of that age group. The analysis also showedthat women receiving warfarin were 3.35 times morelikely to experience a major bleed than men receivingwarfarin.* This study was supported by Procter and Gamble PharmaceuticalCanada, Inc. CARAF received support from Knoll Pharmaceuticals andDuPont Pharma.
Humphries KH, et al. New-onset atrial fibrillation: sex differences in presentation,treatment, and outcome. Circulation 103: 2365-2370, 15 May 2001 800867957
1
Inpharma 30 Jun 2001 No. 12941173-8324/10/1294-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
